Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPMA copolymer-alendronate-TNP-470
- Development stage
- Discontinued
- Lead developer
- Tel Aviv University
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
HPMA copolymer-alendronate-TNP-470 is a targeted, nano-scaled polymer-drug conjugate designed for the treatment of bone-related angiogenesis-dependent malignancies, such as osteosarcoma and bone metastases. It consists of an N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer backbone conjugated to the aminobisphosphonate alendronate (ALN) and the anti-angiogenic agent TNP-470 via a cathepsin K-cleavable tetrapeptide linker (Gly-Gly-Pro-Nle). Alendronate acts as a bone-targeting moiety by binding to hydroxyapatite, while TNP-470 inhibits tumor angiogenesis by targeting methionine aminopeptidase 2 (MetAP2) in endothelial cells. Developed by academic researchers at Tel Aviv University and the University of Utah, this conjugate demonstrates enhanced anti-tumor and anti-angiogenic activity with a superior safety profile and reduced systemic toxicity compared to the free drugs.
- Other names
- HPMA copolymer-ALN-TNP-470
02
Targets
FDPS (Farnesyl pyrophosphate synthase)METAP2 (Methionine aminopeptidase 2)
Beyond the preview
Go deeper on HPMA copolymer-alendronate-TNP-470.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPMA copolymer-alendronate-TNP-470.